Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients

Hepatology

Volumn 30, Issue 4, 1999, Pages 1054-1058

  Benhamou, Yves ^a,b   Bochet, Marie ^a   Di Martino, Vincent ^a   Charlotte, Frederic ^a   Azria, Felipe ^a   Coutellier, Anne ^a   Vidaud, Michel ^a   Bricaire, Francois ^a   Opolon, Pierre ^a   Katlama, Christine ^a   Poynard, Thierry ^a   Mathurin, Philippe ^b   Moussali, Joseph ^b   Sobetski, Rodolphe ^b   Bernard, Brigitte ^b   Blot, Cécile ^b   Perrin, Michèle ^b   Bocher, Marie ^b   Bricaire, François ^b   Danis, Martin ^b   Valantin, Marc Antoine ^b   Tubiana, Roland ^b   Anduze Faris, Béatrice ^b   Duvivier, Claudine ^b   Caumes, Eric ^b   Herson, Serge ^b   Bonmarchand, Manuella ^b   Le Charpentier, Yves ^b   Hureaux, Jean Marie ^b   Costa, Jean Marc ^b   Olivi, Martine ^b   Deckmyn, Olivier ^b   Vidaud, Jean René ^b   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Grp Hosp Pitie Salpetriere ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALCOHOL CONSUMPTION; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL;

ADULT; ALCOHOL DRINKING; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HIV INFECTIONS; HIV SERONEGATIVITY; HUMANS; IMMUNOSUPPRESSION; LIVER CIRRHOSIS; MALE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 0032837102     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510300409     Document Type: Article

References (28)

1. Sherman KE, Freeman S, Harrison S, Andron L. Prevalence of antibodies to hepatitis C virus in patients infected with the human immunodeficiency virus. J Infect Dis 1991;163:414-415.
2. Rumi MG, Colombo M, Grigeri A, Mannucci PM. High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels. Ann Intern Med 1990;112:279-297.
3. Hayashi PH, Flynn N, McCurdy SA, Kuramoto IK, Holland PV, Zeldis JB. Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virus. J Med Virol 1991;33:177-180.
4. Gulick R, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
5. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleosid analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-733.
6. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused haemophiliacs: effects of coinfection with human immunodeficiency virus. J Acquir Immune Defic Syndr 1993;6:602-610.
7. Pol S, Lamorthe B, Trinh Thi N, Thiers V, Carnot F, Zylberberg H, Berthelot P, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol 1998;28:945-950.
8. Quan CM, Krajden M, Grigoriew GA, Salit IE. Hepatitis C virus infection in patients infected with the immunodeficiency virus. Clin Infect Dis 1993;17:117-119.
9. Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hemandez-Quero J, Key C, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5.
10. Sanchez-Quijano A, Andreu J, Gavilan F, Luque F, Abad MA, Soto B, Munor J, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995;14:949-953.
11. Darby SC, Ewart DW, Giangrande PLF, Spooner RJ, Rizza CR, Dusheiko GM, Lee CA, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350:1425-1431.
12. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832.
13. The French METAVIR Cooperative Study Group. Interobserver and intraobserver variation in liver biopsy interpretation in patients with chronic hepatitis C. HEPATOLOGY 1994;20:15-20.
14. Bedossa P, Poynard T, for the METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. HEPATOLOGY 1996;24:289-293.
15. Poynard T, Bedossa P, Chevalier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, et al, and the Multicenter Study Group. A randomized trial of three alfa 2b interferon regimens for long term treatment of patients with chronic non-A non-B hepatitis. N Engl J Med 1995;332:1457-1462.
16. Sobesky R, Mathurin PH, Charlotte F, Moussalli J, Olivi M, Vidaud M, Ratziu V, et al. Modeling the impact of alpha interferon treatment on the natural history of liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 1999;116:378-386
17. Ridzon R, Gallagher K, Ciesielski C, Ginsberg MB, Robertson BJ, Luo CC, DeMaria AJ. Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. N Engl J Med 1997;336:919-922.
18. Mazza C, Puotti M, Ravaggi A, Castelnuovo F, Albertini A, Cariani E. Molecular analysis of mixed infection with hepatitis C virus and human immunodeficiency virus in a patient infected simultaneously. J Med Virol 1996;50:276-282.
19. Martin P, Di Bisceglie AM, Kassianides C, Lisker-Melman M, Hoofnagle JH. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology 1989;97:1559-1561.
20. Shi Z, Wakil AE, Rockey DC. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci U S A 1997;94:10663-10668.
21. Thomas DL, Shih JW, Alter HJ, Vlahov D, Cohn S, Hoover DR, Cheung L, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996;174:690-695.
22. Chazouilleres O, Kim M, Combs C, Ferrell L, Bacchetti P, Roberts J, Ascher NL, et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994;106:994-999.
23. Lucidarme D, Foutrein P, Creusy C, Forzy G, Foutrein-Comes MC, Muyssen A, Bailly D, et al. Prévalence des marqueurs de l'hépatite C, B et D et aspects histopathologiques dans un groupe de toxicomanes intraveineux. Gastroentrol Clin Biol 1994;18:964-968.
24. Mangia A, Cascavilla I, Lezzi G, Spirito F, Maertens G, Parlatore L, Saracco G, et al. HCV genotypes in patients with liver disease of different stages and severity. J Hepatol 1997;26:1173-1178.
25. Feray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, Reynes M, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995;108:1088-1096.
26. Rutschmann OT, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin LH. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998;177:783-785.
27. Brau N, Leaf HL, Wieczorek RL, Margolis DM. Severe hepatitis in three AIDS patients treated with indinavir. Lancet 1997;349:924-925.
28. Soriano V, Garcia-Samaniego J, Bravo R, Gonzalez J, Gastro A, Castilla J, Martinez-Odriozda P, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23:585-591.